Tango Therapeutics (TNGX) Non Operating Income (2020 - 2026)

Tango Therapeutics' Non Operating Income history runs 7 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 21.13% year-over-year to $3.3 million in Q1 2026; TTM through Mar 2026 was $10.3 million, a 25.64% decrease from a year earlier, with the FY2025 full-year figure at $9.7 million, down 37.43% from the prior year.
• Non Operating Income advanced to $3.3 million in Q1 2026 per TNGX's latest filing, from $3.1 million in the prior quarter.
• Across five years, Non Operating Income topped out at $4.4 million in Q1 2024 and bottomed at $171000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $2.7 million (2025), against an average of $2.6 million.
• Across the five-year window, Non Operating Income soared 2029.27% in 2022 and tumbled 52.14% in 2025, its largest moves.
• Year by year, Non Operating Income stood at $1.6 million in 2022, then surged by 175.8% to $4.3 million in 2023, then declined by 23.46% to $3.3 million in 2024, then declined by 6.96% to $3.1 million in 2025, then advanced by 6.41% to $3.3 million in 2026.
• Per Business Quant, the three latest TNGX Non Operating Income figures stand at $3.3 million (Q1 2026), $3.1 million (Q4 2025), and $1.8 million (Q3 2025).